NASDAQ:CTSO

Cytosorbents Stock Insider Trading

Healthcare > Medical - Devices

Buy CTSO

*Your capital is at risk

$0.361

+0.0108 (+3.08%)

At Close: Jul 31, 2026

Cytosorbents Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 80.20. In total, the insiders bought 3.77M and sold 651.8K CTSO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	80.20
● Buy	3.77M shares
● Sell	651.8K shares
78% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jun 15, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 80.2. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (78% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 17, 2025 Buy	Common Stock X-InTheMoney	Mariani Peter J Chief Financial Officer	C-Suite Officer	32 625 Value: $32.6K
Jan 17, 2025 Sell	Subscription Rights (right to buy) X-InTheMoney	Chan Phillip P. Chief Executive Officer	CEO / President	90 832 Value: $90.8K
Jan 17, 2025 Buy	Series B Right Warrants J-Other	Chan Phillip P. Chief Executive Officer	CEO / President	90 832 Value: $93.6K
Jan 17, 2025 Buy	Series A Right Warrants J-Other	Chan Phillip P. Chief Executive Officer	CEO / President	90 832 Value: $93.6K
Jan 17, 2025 Buy	Common Stock X-InTheMoney	Chan Phillip P. Chief Executive Officer	CEO / President	90 832 Value: $90.8K
Jan 17, 2025 Sell	Subscription Rights (right to buy) X-InTheMoney	Sobel Alan D. Director	Director	21 950 Value: $22.0K
Jan 17, 2025 Buy	Series B Right Warrants J-Other	Sobel Alan D. Director	Director	21 950 Value: $22.6K
Jan 17, 2025 Buy	Series A Right Warrants J-Other	Sobel Alan D. Director	Director	21 950 Value: $22.6K
Jan 17, 2025 Buy	Common Stock X-InTheMoney	Sobel Alan D. Director	Director	21 950 Value: $22.0K
Jan 17, 2025 Sell	Subscription Rights (right to buy) X-InTheMoney	Deliargyris Efthymios Chief Medical Officer	Officer	16 233 Value: $16.2K
Jan 17, 2025 Buy	Series B Right Warrants J-Other	Deliargyris Efthymios Chief Medical Officer	Officer	16 233 Value: $16.7K
Jan 17, 2025 Buy	Series A Right Warrants J-Other	Deliargyris Efthymios Chief Medical Officer	Officer	16 233 Value: $16.7K
Jan 17, 2025 Buy	Common Stock X-InTheMoney	Deliargyris Efthymios Chief Medical Officer	Officer	16 233 Value: $16.2K
Jan 17, 2025 Sell	Subscription Rights (right to buy) X-InTheMoney	Capponi Vincent President And COO	CEO / President	31 760 Value: $31.8K
Jan 17, 2025 Buy	Series B Right Warrants J-Other	Capponi Vincent President And COO	CEO / President	31 760 Value: $32.7K
Jan 17, 2025 Buy	Series A Right Warrants J-Other	Capponi Vincent President And COO	CEO / President	31 760 Value: $32.7K
Jan 17, 2025 Buy	Common Stock X-InTheMoney	Capponi Vincent President And COO	CEO / President	31 760 Value: $31.8K
Jan 17, 2025 Sell	Subscription Rights (right to buy) X-InTheMoney	Bator Michael G. Director	Director	15 879 Value: $15.9K
Jan 17, 2025 Buy	Series B Right Warrants J-Other	Bator Michael G. Director	Director	15 879 Value: $16.4K
Jan 17, 2025 Buy	Series A Right Warrants J-Other	Bator Michael G. Director	Director	15 879 Value: $16.4K
Jan 17, 2025 Buy	Common Stock X-InTheMoney	Bator Michael G. Director	Director	15 879 Value: $15.9K
Dec 13, 2024 Buy	Common Stock P-Purchase	Mariani Peter J Chief Financial Officer	C-Suite Officer	20 000 Value: $19.3K
Dec 13, 2024 Buy	Common Stock P-Purchase	Mariani Peter J Chief Financial Officer	C-Suite Officer	20 000 Value: $19.3K
Dec 12, 2024 Buy	Common Stock P-Purchase	Mariani Peter J Chief Financial Officer	C-Suite Officer	20 000 Value: $17.9K
Dec 11, 2024 Buy	Common Stock P-Purchase	Mariani Peter J Chief Financial Officer	C-Suite Officer	11 363 Value: $10.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CYTOSORBENTS CORPORATION

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complication...

Read Full Profile Here